Should I buy or sell Bio-Path stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTH shares. View BPTH analyst ratings or view top-rated stocks .

What is Bio-Path's stock price target for 2024?

1 brokerages have issued 12 month price objectives for Bio-Path's stock. Their BPTH share price targets range from $40.00 to $40.00. On average, they predict the company's share price to reach $40.00 in the next year. This suggests a possible upside of 1,207.2% from the stock's current price. View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts .

How have BPTH shares performed in 2024?

Bio-Path's stock was trading at $9.26 at the start of the year. Since then, BPTH shares have decreased by 67.0% and is now trading at $3.06. View the best growth stocks for 2024 here .

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest in March. As of March 31st, there was short interest totaling 67,400 shares, an increase of 6.3% from the March 15th total of 63,400 shares. Based on an average daily trading volume, of 24,900 shares, the days-to-cover ratio is currently 2.7 days. Approximately 9.0% of the shares of the company are sold short. View Bio-Path's Short Interest .

When is Bio-Path's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BPTH earnings forecast .

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its quarterly earnings results on Friday, March, 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($5.40). During the same period last year, the business earned ($10.60) earnings per share.

When did Bio-Path's stock split?

Shares of Bio-Path reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA) , Palatin Technologies (PTN) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Amarin (AMRN) , Trevena (TRVN) , Energy Transfer (ET) , Anavex Life Sciences (AVXL) and Biocept (BIOC) .

How do I buy shares of Bio-Path?

Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BPTH

Bio-Path (BPTH) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free BPTH Stock Alerts

$2.92

-0.02 (-0.68%)

(As of 03:39 PM ET)

Compare

Today's Range: $2.71
▼
$3.15
50-Day Range: $2.95
▼
$9.30
52-Week Range: $2.71
▼
$44.80

Volume: 15,337 shs
Average Volume: 24,426 shs
Market Capitalization: $1.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $40.00

Get Bio-Path alerts:

Bio-Path MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,207.2% Upside
$40.00 Price Target
Short Interest: Bearish
8.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.13
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($18.71) to ($18.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.16 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Bio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Bio-Path has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.97% of the float of Bio-Path has been sold short.
Short Interest Ratio / Days to Cover
Bio-Path has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Path has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Bio-Path does not currently pay a dividend.
Dividend Growth
Bio-Path does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTH.

1.7

News and Social Media Coverage

News Sentiment
Bio-Path has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Bio-Path this week, compared to 1 article on an average week.
MarketBeat Follows
Only 3 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Path insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.05% of the stock of Bio-Path is held by insiders.
Percentage Held by Institutions
Only 5.74% of the stock of Bio-Path is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Bio-Path are expected to grow in the coming year, from ($18.71) to ($18.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Path is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Path is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Path has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Bio-Path Stock (NASDAQ:BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

BPTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPTH Stock News Headlines

April 16, 2024 | americanbankingnews.com

Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

April 15, 2024 | baystreet.ca

BioPath Hikes on International Patents

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 15, 2024 | globenewswire.com

Bio-Path Holdings Expands Global Patent Portfolio

April 13, 2024 | morningstar.com

Bio-Path Holdings Inc BPTH

April 8, 2024 | americanbankingnews.com

Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

April 6, 2024 | americanbankingnews.com

Q1 2024 Earnings Forecast for Bio-Path Holdings, Inc. (NASDAQ:BPTH) Issued By Roth Capital

April 5, 2024 | msn.com

Discovery of a fundamental biological mechanism opens path for novel therapies

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 4, 2024 | msn.com

Bio-Path Holdings shares sink 6% after deal for at-the-market offering

April 2, 2024 | globenewswire.com

Bio-Path Holdings Provides 2024 Clinical and Operational Update

March 26, 2024 | msn.com

Bharat Biotech starts TB vaccine’s trials in adults

March 25, 2024 | marketwatch.com

Bio-Path Shares Close Lower After Withdrawing S-1

March 13, 2024 | insidermonkey.com

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

March 10, 2024 | seekingalpha.com

Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript

March 10, 2024 | finance.yahoo.com

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript

March 8, 2024 | msn.com

Why Bio-Path Holdings Shares Are Falling Today

March 8, 2024 | msn.com

Bio-Path files to sell 1.15M shares of common stock, warrants

March 8, 2024 | finanznachrichten.de

Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2023 Financial Results

March 8, 2024 | globenewswire.com

Bio-Path Holdings Reports Full Year 2023 Financial Results

March 7, 2024 | benzinga.com

Bio-Path Holdings's Earnings: A Preview

March 1, 2024 | globenewswire.com

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024

February 24, 2024 | msn.com

Bio-Path Holdings (BPTH) Price Target Increased by 1900.00% to 244.80

February 22, 2024 | benzinga.com

Bio-Path Hldgs Stock (NASDAQ:BPTH) Dividends: History, Yield and Dates

February 21, 2024 | finanznachrichten.de

Bio-Path Holdings, Inc.: Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

February 21, 2024 | finance.yahoo.com

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

February 21, 2024 | globenewswire.com

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

See More Headlines

Receive BPTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BPTH
CUSIP: N/A
CIK: 1133818
Web: www.biopathholdings.com
Phone: (832) 742-1357
Fax: N/A
Employees: 10
Year Founded: 2007

Price Target and Rating

Average Stock Price Target: $40.00
High Stock Price Target: $40.00
Low Stock Price Target: $40.00
Potential Upside/Downside: +1,255.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($40.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,080,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -375.74%
Return on Assets: -248.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.60
Quick Ratio: 1.60

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 4.15

Miscellaneous

Outstanding Shares: 680,000
Free Float: 658,000
Market Cap: $2.01 million
Optionable: Optionable
Beta: 0.36

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Peter H. Nielsen MBA (Age 75)
Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer
Comp: $696.24k
Mr. Douglas P. Morris (Age 68)
Co-Founder, Director of Investor Relations, Secretary & Director
Comp: $73.74k
Mr. Michael Hickey M.B.A.
VP of Clinical Operations
Mr. Anthony Price
Senior Vice President of Finance, Accounting & Administration
Dr. Ana Tari Ashizawa Ph.D.
MBA, Senior Vice President of Research, Development & Clinical Design

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BPTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Path stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTH shares.
View BPTH analyst ratings or view top-rated stocks.
What is Bio-Path's stock price target for 2024?: 1 brokerages have issued 12 month price objectives for Bio-Path's stock. Their BPTH share price targets range from $40.00 to $40.00. On average, they predict the company's share price to reach $40.00 in the next year. This suggests a possible upside of 1,207.2% from the stock's current price.
View analysts price targets for BPTH or view top-rated stocks among Wall Street analysts.
How have BPTH shares performed in 2024?: Bio-Path's stock was trading at $9.26 at the start of the year. Since then, BPTH shares have decreased by 67.0% and is now trading at $3.06.
View the best growth stocks for 2024 here.
Are investors shorting Bio-Path?: Bio-Path saw a increase in short interest in March. As of March 31st, there was short interest totaling 67,400 shares, an increase of 6.3% from the March 15th total of 63,400 shares. Based on an average daily trading volume, of 24,900 shares, the days-to-cover ratio is currently 2.7 days. Approximately 9.0% of the shares of the company are sold short.
View Bio-Path's Short Interest.
When is Bio-Path's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BPTH earnings forecast.

How were Bio-Path's earnings last quarter?: Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its quarterly earnings results on Friday, March, 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($5.40). During the same period last year, the business earned ($10.60) earnings per share.
When did Bio-Path's stock split?: Shares of Bio-Path reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Bio-Path own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).
How do I buy shares of Bio-Path?: Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPTH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bio-Path (BPTH) Stock Price, News & Analysis

Bio-Path MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Bio-Path Stock (NASDAQ:BPTH)

BPTH Stock Price History

BPTH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

BPTH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™